Attached files
| file | filename |
|---|---|
| EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL - Phio Pharmaceuticals Corp. | phio_ex3101.htm |
| EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Phio Pharmaceuticals Corp. | phio_ex2301.htm |
| EX-10.3 - FORM OF RESTRICTED STOCK UNIT AWARD - Phio Pharmaceuticals Corp. | phio_ex1003.htm |
| 10-K - FORM 10-K - Phio Pharmaceuticals Corp. | phio_10k-123120.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Phio Pharmaceuticals Corp. (the “Company”) on Form 10-K for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations. |
|
/s/ Gerrit Dispersyn |
|
| Gerrit Dispersyn, Dr. Med. Sec. | |
| President and Chief Executive | |
| (Principal Executive Officer and Principal Financial Officer) | |
Dated: March 25, 2021